Drug intelligence / Profile preview

CADI-R402

Development stage: Preclinical
Lead developer: Bio-Modeling Systems

Overview

CADI-R402 is a therapeutic research program developed by Bio-Modeling Systems (BMSystems) focused on metabolic disorders. The program utilizes the company's proprietary CADI (Computer Assisted Deductive Integration) platform, which employs a non-mathematical heuristic modeling approach to integrate multi-disciplinary biological data. This specific program aims to identify and validate novel therapeutic targets and mechanisms within metabolic pathways. While the exact molecular target or modality is not publicly disclosed, the program is part of BMSystems' broader effort to address complex metabolic syndromes and related epigenetic/metabolic dysfunctions through systems biology-driven discovery.

Beyond the preview

Go deeper on CADI-R402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CADI-R402.

Explore the full profile